Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

133
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
133
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

220
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
220
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

211
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
211
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

305
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
305

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

High-dose linezolid during BPaL implementation for pre-extensively drug-resistant TB or failure/intolerance of rifampicin-resistant TB regimens.

IJTLD open·2026
Same author

The Kochi Declaration 2024 - A catalyst for global TB elimination through private sector engagement.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same author

High efficacy of BPaL among patients infected with <i>Mycobacterium tuberculosis</i> lineage 1 in the Philippines.

IJTLD open·2026
Same author

The time is now: making the case for compassionate use/pre-approval access to new TB drugs.

IJTLD open·2025
Same author

Laboratory strengthening strategies to advance drug susceptibility testing for BPaL regimens in TB treatment.

Public health action·2025
Same author

Treatment success rate and time to culture conversion under a prospective BPaL cohort study.

IJTLD open·2025

相关实验视频

Updated: Jun 7, 2025

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA
10:41

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA

Published on: April 30, 2020

13.9K

介绍BPaL:来自LIFT-TB项目支持的国家的经验

D F Wares1, M Mbenga1, V Mirtskhulava1

  • 1KNCV Tuberculosis Foundation, The Hague, The Netherlands.

PloS one
|November 19, 2024
PubMed
概括

针对耐药结核病 (DR-TB) 的新的6个月BPaL疗法显示出高的成功率,并且在不同的国家都是可行的. 这种全口服治疗对DR-TB患者是安全有效的.

更多相关视频

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

11.8K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K

相关实验视频

Last Updated: Jun 7, 2025

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA
10:41

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA

Published on: April 30, 2020

13.9K
An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

11.8K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K

科学领域:

  • 全球健康 全球健康
  • 传染性疾病 传染性疾病
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 耐药结核病 (DR-TB) 治疗历史上涉及长期,有毒和效率较低的疗法.
  • 最近的进展包括世界卫生组织的2020年指导方针,建议在经营研究 (OR) 中为选择的DR-TB患者提供6个月的全口服BPaL (bedaquiline, pretomanid, linezolid) 治疗方案.

研究的目的:

  • 评估在操作研究 (OR) 条件下为DR-TB患者引入BPaL治疗方案的可行性,有效性和安全性.
  • 通过LIFT-TB项目评估7个国家的实施过程和挑战.

主要方法:

  • 在2020年11月至2023年3月期间,LIFT-TB项目在7个国家招募了574名DR-TB患者.
  • 运营研究的目标集中在探索BPaL疗法引入的可行性,并估计其有效性和安全性.

主要成果:

  • 在被录取的患者中,临时治疗成功率达到90.9% (280/308).
  • 特别感兴趣的不良事件 (AESI) 是常见的,但可以管理的,只有一个患者停止治疗.
  • 在研究期间没有观察到意外不良事件 (AE).

结论:

  • 通过强有力的宣传和合作伙伴沟通,BPaL OR 方案在不同的国家环境中被证明是可行的.
  • 临时结果显示患者反应很好,与临床试验结果相比.
  • 可管理的不良事件和没有意想不到的AEs支持BPaL治疗方案在现实环境中的安全概况.